At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Market Closed 04-24 16:00:00 EDT
13.81
-0.81
-5.54%
盘后14.20
+0.39+2.82%
19:53 EDT
High14.88Low13.68Vol1.08M
Open14.59D1 Closing14.62Amplitude8.21%
Mkt Cap674.58MTradable Cap397.30MTotal Shares48.85M
T/O15.26MT/O Rate3.74%Tradable Shares28.77M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clene, Lovesac, HDFC Bank, State Street, Vor Shock
TIPRANKS  ·  04-25 21:01
Clene, Lovesac, HDFC Bank, State Street, Vor Shock
Major Vor Biopharma Insider Makes a Multi-Million Dollar Move
TIPRANKS  ·  04-25 10:01
Major Vor Biopharma Insider Makes a Multi-Million Dollar Move
RA Capital Management disposes 165,150 Vor Biopharma shares worth $2.6 million
Reuters  ·  04-25 06:13
RA Capital Management disposes 165,150 Vor Biopharma shares worth $2.6 million
Major Insider Move Rocks Vor Biopharma as Director Unloads Massive Stake
TIPRANKS  ·  04-22
Major Insider Move Rocks Vor Biopharma as Director Unloads Massive Stake
RA Capital Healthcare Fund disposes Vor Biopharma shares worth $10.2 million
Reuters  ·  04-22
RA Capital Healthcare Fund disposes Vor Biopharma shares worth $10.2 million
Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
TIPRANKS  ·  04-18
Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
Major Insider Shake-Up at Vor Biopharma as Key Stakeholder Trims Position
TIPRANKS  ·  04-16
Major Insider Shake-Up at Vor Biopharma as Key Stakeholder Trims Position
RA Capital Management disposes Vor Biopharma common shares worth $11.9 million
Reuters  ·  04-16
RA Capital Management disposes Vor Biopharma common shares worth $11.9 million
Vor Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  04-15
Vor Biopharma Is Maintained at Buy by HC Wainwright & Co.
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
TIPRANKS  ·  04-11
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
Major Insider Move Shakes Up Vor Biopharma Trading Activity
TIPRANKS  ·  04-11
Major Insider Move Shakes Up Vor Biopharma Trading Activity
RA Capital Healthcare Fund disposes Vor Biopharma shares worth $10.3 million
Reuters  ·  04-11
RA Capital Healthcare Fund disposes Vor Biopharma shares worth $10.3 million
Vor Biopharma files Form 3 for new Chief Medical Officer Jeremy Brett Sokolove
Reuters  ·  04-10
Vor Biopharma files Form 3 for new Chief Medical Officer Jeremy Brett Sokolove
Major Insider Move Rocks Vor Biopharma as Director Unloads Massive Stake
TIPRANKS  ·  04-07
Major Insider Move Rocks Vor Biopharma as Director Unloads Massive Stake
RA Capital Management disposes of Vor Biopharma common shares worth $14.6 million
Reuters  ·  04-07
RA Capital Management disposes of Vor Biopharma common shares worth $14.6 million
BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  04-02
BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC
Reuters  ·  04-02
Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC
Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule
Reuters  ·  04-02
Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule
Vor Biopharma Is Maintained at Neutral by Wedbush
Dow Jones  ·  03-31
Vor Biopharma Is Maintained at Neutral by Wedbush
Vor Bio price target raised to $15 from $9 at Wedbush
TIPRANKS  ·  03-31
Vor Bio price target raised to $15 from $9 at Wedbush

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--